BiotechTube
Amnio Technology

Amnio Technology

Phoenix, United States· Est.
amniotechnology.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Amnio Technology, founded in 2008 and headquartered in Phoenix, Arizona, is a private company commercializing a portfolio of amniotic allograft products under the PalinGen® brand. Its core differentiator is a proprietary manufacturing process (Advantec©) that removes the chorion layer, which it claims reduces immunogenic risk. The company is in the commercial stage, selling its products to hospitals and clinics nationwide for wound care and orthopedic indications, with a reported track record of zero adverse events and over 0K+ products implanted.

Wound CareOrthopedics

Technology Platform

Proprietary Advantec© process for manufacturing chorion-free amniotic membrane and liquid allografts, aimed at reducing immunogenicity.

Opportunities

The growing advanced wound care and orthopedic biologics market, driven by demographic trends, presents a significant expansion opportunity.
Securing specific HCPCS Q-codes facilitates reimbursement and eases adoption by healthcare providers.
The company's claimed zero adverse event record is a powerful marketing tool to differentiate in a competitive landscape.

Risk Factors

Regulatory changes for HCT/Ps or shifts in insurance reimbursement policies could disrupt the business model.
Intense competition from other amniotic tissue processors and broader regenerative medicine companies threatens market share.
The company is reliant on a consistent supply of donated tissue and must maintain stringent quality control to avoid supply or safety issues.

Competitive Landscape

Amnio Technology competes in the crowded amniotic tissue allograft market against companies like Organogenesis (NuCel®, PuraPly®), MiMedx (Epifix®, AmnioFix®), and StimLabs. Its primary differentiation is the chorion-free manufacturing claim. It also faces competition from alternative regenerative technologies including platelet-rich plasma (PRP), other birth tissue products, and synthetic scaffolds.

More companies in Biologics / Biosimilars →More companies in United States →